Anti-Tumor Antibodies

Chondroition sulfate proteoglycans represent excellent targets for anti-tumor immunotherapy. Antibodies which target such proteoglycans can be used alone, in combinations, armed with a cytotoxic payload or unarmed. Combinations of such antibodies can target different epitopes of the proteoglycans. Internalization of the antibodies can increase the toxicity of the payloads. Single chain variable regions are especially advantageous for such anti-tumor immunotherapy.

Patents:
US 20,100,047,164

Inventor(s): BIGNER DARELL [US]; KUAN CHIEN-TSUN [US]; PASTAN IRA H [US]; REISFELD RALPH [US]

Type of Offer: Licensing



« More Medical Patents

---